The use of the NEDD8 inhibitor MLN4924 (Pevonedistat) in a cyclotherapy approach to protect wild-type p53 cells from MLN4924 induced toxicity

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Malhab, Lara J Bou ^a   Descamps, Simon ^a   Delaval, Benedicte ^a   Xirodimas, Dimitris P ^a  

^a UNIV MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPENTANE DERIVATIVE; NEDD8 PROTEIN; NEDD8 PROTEIN, HUMAN; PEVONEDISTAT; PROTEIN P53; PYRIMIDINE DERIVATIVE; UBIQUITIN;

ANTAGONISTS AND INHIBITORS; APOPTOSIS; DRUG EFFECT; HCT 116 CELL LINE; HUMAN; METABOLISM; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CYCLOPENTANES; HCT116 CELLS; HUMANS; NEDD8 PROTEIN; PYRIMIDINES; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITINS;

EID: 85000400157     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep37775     Document Type: Article

References (32)

1. Abidi, N., Xirodimas, D. P. Regulation of cancer-related pathways by protein NEDDylation and strategies for the use of NEDD8 inhibitors in the clinic. Endocr. Relat. Cancer 22, T55-T70 (2015).
2. Enchev, R. I., Schulman, B. A., Peter, M. Protein neddylation: beyond cullin-RING ligases. Nat. Rev. Mol. Cell Biol. 16, 30-44 (2014).
3. Xirodimas, D. P. Novel substrates and functions for the ubiquitin-like molecule NEDD8: Figure 1. Biochem. Soc. Trans. 36, 802-806 (2008).
4. Barbier-Torres, L. et al. Stabilization of LKB1 and Akt by neddylation regulates energy metabolism in liver cancer. Oncotarget 6, 2509-2523 (2015).
5. Chairatvit, K., Ngamkitidechakul, C. Control of cell proliferation via elevated NEDD8 conjugation in oral squamous cell carcinoma. Mol. Cell. Biochem. 306, 163-169 (2007).
6. Li, L. et al. Overactivated Neddylation Pathway as a Therapeutic Target in Lung Cancer. JNCI J. Natl. Cancer Inst. 106, 83-83 (2014).
7. Soucy, T. A. et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458, 732-736 (2009).
8. Soucy, T. A., Dick, L. R., Smith, P. G., Milhollen, M. A., Brownell, J. E. The NEDD8 Conjugation Pathway and Its Relevance in Cancer Biology and Therapy. Genes Cancer 1, 708-716 (2010).
9. Wang, M. et al. Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer. Expert Opin. Ther. Targets 15, 253-264 (2011).
10. Swords, R. T. et al. Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study. Br. J. Haematol. 169, 534-543 (2015).
11. Blagosklonny, M. V. Analysis of FDA approved anticancer drugs reveals the future of cancer therapy. Cell Cycle Georget. Tex 3, 1035-1042 (2004).
12. Rao, B., Lain, S., Thompson, A. M. p53-Based cyclotherapy: exploiting the 'guardian of the genome' to protect normal cells from cytotoxic therapy. Br. J. Cancer 109, 2954-2958 (2013).
13. Blagosklonny, M. V., Pardee, A. B. Exploiting cancer cell cycling for selective protection of normal cells. Cancer Res. 61, 4301-4305 (2001).
14. Kranz, D., Dobbelstein, M. Nongenotoxic p53 Activation Protects Cells against S-Phase-Specific Chemotherapy. Cancer Res. 66, 10274-10280 (2006).
15. van Leeuwen, I. M. M. Cyclotherapy: opening a therapeutic window in cancer treatment. Oncotarget 3, 596-600 (2012).
16. van Leeuwen, I. M. M., Rao, B., Sachweh, M. C. C., Lain, S. An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells. Cell Cycle 11, 1851-1861 (2012).
17. Hollstein, M., Sidransky, D., Vogelstein, B., Harris, C. C. p53 mutations in human cancers. Science 253, 49-53 (1991).
18. Vousden, K. H., Lu, X. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2, 594-604 (2002).
19. Sur, S. et al. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc. Natl. Acad. Sci. 106, 3964-3969 (2009).
20. Kim, Y., Kipreos, E. T. Cdt1 degradation to prevent DNA re-replication: conserved and non-conserved pathways. Cell Div. 2, 18 (2007).
21. Choong, M. L., Yang, H., Lee, M. A., Lane, D. P. Specific activation of the p53 pathway by low dose actinomycin D: A new route to p53 based cyclotherapy. Cell Cycle 8, 2810-2818 (2009).
22. Perry, R. P., Kelley, D. E. Inhibition of RNA synthesis by actinomycin D: Characteristic dose-response of different RNA species. J. Cell. Physiol. 76, 127-139 (1970).
23. Murray-Zmijewski, F., Lane, D. P., Bourdon, J. C. p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ. 6, 962-72 (2006).
24. Spitsbergen, J. M., Kent, M. L. The state of the art of the zebrafish model for toxicology and toxicologic pathology research-advantages and current limitations. Toxicol. Pathol. 31 Suppl, 62-87 (2003).
25. Dimopoulos, M. A., Terpos, E. Hematology: First-line bortezomib benefits patients with multiple myeloma. Nat. Rev. Clin. Oncol. 6, 683-685 (2009).
26. Emanuele, M. J. et al. Global Identification of Modular Cullin-RING Ligase Substrates. Cell 147, 459-474 (2011).
27. Bailly, A. et al. The NEDD8 inhibitor MLN4924 increases the size of the nucleolus and activates p53 through the ribosomal-Mdm2 pathway. Oncogene 35, 415-426 (2016).
28. Lin, J. J., Milhollen, M. A., Smith, P. G., Narayanan, U., Dutta, A. NEDD8-Targeting Drug MLN4924 Elicits DNA Rereplication by Stabilizing Cdt1 in S Phase, Triggering Checkpoint Activation, Apoptosis, and Senescence in Cancer Cells. Cancer Res. 70, 10310-10320 (2010).
29. Komarov, P. G. et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285, 1733-1737 (1999).
30. Westerfield, M. The Zebrafish Book: A Guide for the Laboratory Use of Zebrafish (Danio Rerio) (University of Oregon Press) (2007).
31. Sorrells, S., Toruno, C., Stewart, R. A., Jette, C. Analysis of Apoptosis in Zebrafish Embryos by Whole-mount Immunofluorescence to Detect Activated Caspase 3. J. Vis. Exp, doi: 10.3791/51060 (2013).
32. Lee, K.-C. et al. Detection of the p53 response in zebrafish embryos using new monoclonal antibodies. Oncogene 27, 629-640 (2008).